Aligos Therapeutics Inc. (ALGS)
ALGS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$5.51
-0.36% on the day
Market cap
$34.4M
Nano cap
Revenue · 2025
$2.2M
-39.5% on 2024
Net income · 2025
-$24.2M
-1106.7% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ALGS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001799448 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.2M |
| Net income | -$24.2M |
| Operating income | -$88.0M |
| Net margin | -1106.7% |
| Operating margin | -4024.9% |
| Revenue growth | -39.5% |
| Cash | $18.3M |
| Total assets | $88.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 15.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-04-03 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-09-15 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 346 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ELUT | Elutia Inc. | $0.7732 | -1.75% | $34.2M |
| MGX | Metagenomi Therapeutics Inc. | $0.9173 | -10.07% | $34.7M |
| GNTA | Genenta Science S.p.A. | $0.7220 | -4.99% | $34.8M |
| CVM | Cel-Sci Corporation | $1.75 | -4.37% | $30.8M |
| TIL | Instil Bio Inc. | $6.18 | -6.08% | $41.9M |
| BSEM | BioStem Technologies Inc. | $2.25 | -7.79% | $42.0M |
| EXOZ | eXoZymes Inc. | $4.59 | -9.11% | $42.7M |
| INMB | INmune Bio Inc. | $1.68 | -5.62% | $46.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier